Mechanism of Gegen Qinlian Decoction in treatment of ulcerative colitis through affecting bile acid synthesis.
10.19540/j.cnki.cjcmm.20241212.708
- Author:
Yi-Xuan SUN
1
;
Jia-Li FAN
1
;
Jing-Jing WU
2
;
Li-Juan CHEN
1
;
Jiang-Hua HE
1
;
Wen-Juan XU
1
;
Ling DONG
1
Author Information
1. School of Life Sciences,Beijing University of Chinese Medicine Beijing 100029,China.
2. School of Chinese Materia Medica,Beijing University of Chinese Medicine Beijing 100029,China.
- Publication Type:Journal Article
- Keywords:
Gegen Qinlian Decoction;
bile acid synthesis;
ulcerative colitis
- MeSH:
Animals;
Colitis, Ulcerative/genetics*;
Bile Acids and Salts/biosynthesis*;
Drugs, Chinese Herbal/administration & dosage*;
Mice;
Male;
Humans;
Receptors, Cytoplasmic and Nuclear/metabolism*;
Colon/metabolism*;
Disease Models, Animal;
Liver/metabolism*;
Mice, Inbred C57BL
- From:
China Journal of Chinese Materia Medica
2025;50(10):2769-2777
- CountryChina
- Language:Chinese
-
Abstract:
Gegen Qinlian Decoction(GQD) is a classic prescription for the clinical treatment of ulcerative colitis(UC). This study, based on the differences in efficacy observed in UC mice under different level of bile acids treated with GQD, aims to clarify the impact of bile acids on UC and its therapeutic effects. It further investigates the expression of bile acid receptors in the liver of UC mice, and preliminarily reveals the mechanism through which GQD affects bile acid synthesis in the treatment of UC. A UC mouse model was established using dextran sulfate sodium(DSS) induction. The efficacy of GQD was evaluated by assessing the general condition, disease activity index(DAI) score, colon length, and histopathological changes in colon tissue via hematoxylin and eosin(HE) staining. ELISA and Western blot were used to evaluate the inflammatory response in colon tissue. The total bile acid(TBA) level and liver damage were quantified using an automatic biochemistry analyzer. The expression levels of bile acid receptors and bile acid synthetases in liver tissue were detected by Western blot and RT-qPCR. The results showed that compared with the model group, GQD treatment significantly improved the DAI score, colon shortening, and histopathological damage in UC mice. The levels of pro-inflammatory factors TNF-α and IL-6 in the colon were significantly reduced. Serum TBA levels were significantly decreased, while alkaline phosphatase(ALP) levels significantly increased. After administration of cholic acid(CA), UC symptoms in the CA + GQD group were significantly aggravated compared with the GQD group. The DAI score, degree of weight loss, colon injury, serum TBA, and liver injury markers all increased significantly. However, compared with the CA group, the CA + GQD group showed a marked reduction in TBA levels and a significant improvement in UC-related symptoms, indicating that GQD can alleviate UC damage exacerbated by CA. Further investigation into the expression of bile acid receptors and synthetases in the liver showed that under GQD treatment, the expression of farnesoid X receptor(FXR) and small heterodimer partner(SHP) significantly increased, while the expression of G protein-coupled receptor 5(TGR5) and cholesterol 7α-hydroxylase(Cyp7A1) significantly decreased. These findings suggest that GQD may affect bile acid receptors and synthetases, inhibiting bile acid synthesis through the FXR/SHP pathway to treat UC.
